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The 6-Aminoquinolone WC5 Inhibits Different Functions of the
Immediate-Early 2 (IE2) Protein of Human Cytomegalovirus That Are
Essential for Viral Replication
Beatrice Mercorelli,a Anna Luganini,b Giulia Muratore,a Serena Massari,c Maria Elena Terlizzi,b Oriana Tabarrini,c Giorgio Gribaudo,b
Giorgio Palù,a Arianna Loregiana
Department of Molecular Medicine, University of Padua, Padua, Italya; Department of Life Sciences and Systems Biology, University of Turin, Turin, Italyb; Department of
Chemistry and Technology of Drugs, University of Perugia, Perugia, Italyc
The human cytomegalovirus (HCMV) immediate-early 2 (IE2) protein is a multifunctional factor essential for viral replication.
IE2 modulates both viral and host gene expression, deregulates cell cycle progression, acts as an immunomodulator, and antago-
nizes cellular antiviral responses. Based on these facts, IE2 has been proposed as an important target for the development of in-
novative antiviral approaches. We previously identified the 6-aminoquinoloneWC5 as a promising inhibitor of HCMV replica-
tion, and here, we report the dissection of its mechanism of action against the viral IE2 protein. Using glutathione S-transferase
(GST) pulldown assays, mutagenesis, cell-based assays, and electrophoretic mobility shift assays, we demonstrated thatWC5
does not interfere with IE2 dimerization, its interaction with TATA-binding protein (TBP), and the expression of a set of cellular
genes that are stimulated by IE2. On the contrary, WC5 targets the regulatory activity exerted by IE2 on different responsive viral
promoters. Indeed, WC5 blocked the IE2-dependent negative regulation of the major immediate-early promoter by preventing
IE2 binding to the crs element. Moreover, WC5 reduced the IE2-dependent transactivation of a series of indicator constructs
driven by different portions of the earlyUL54 gene promoter, and it also inhibited the transactivation of the murine CMV early
E1 promoter by the IE3 protein, the murine cytomegalovirus (MCMV) IE2 homolog. In conclusion, our results indicate that the
overall anti-HCMV activity ofWC5 depends on its ability to specifically interfere with the IE2-dependent regulation of viral pro-
moters. Importantly, our results suggest that this mechanism is conserved in murine CMV, thus paving the way for further pre-
clinical evaluation in an animal model.
Human cytomegalovirus (HCMV) is one of the most commonopportunistic viral pathogens in immunocompromised indi-
viduals and plays an important pathogenic role in chronic inflam-
matory diseases (1). Indeed, in transplant recipients, AIDS pa-
tients, and immunosuppressed individuals, HCMV represents an
important cause of morbidity and mortality, as viral infection is
associated with pneumonia, gastroenteritis, retinitis, and other
life-threatening diseases (1). In addition, HCMV is the leading
viral cause of congenital birth defects (1).
To date, to prevent and treat HCMV infections, there is no
vaccine available, and only a limited number of drugs are li-
censed for treatment: ganciclovir (GCV), its oral prodrug val-
ganciclovir, foscarnet, acyclovir, its prodrug valacyclovir, and
cidofovir (2–4). The clinical utility of the current anti-HCMV
drugs often has several drawbacks, such as an unfavorable
safety profile characterized by severe acute and long-term tox-
icities and poor oral bioavailability that for some drugs re-
quires intravenous administration (2). Moreover, no drugs
have been approved for the treatment of congenital infection
(5). The antiviral therapy is further complicated by the emer-
gence of cross-resistant clinical strains, as the anti-HCMV
compounds approved so far share a mechanism of action that
targets the viral DNA polymerase (2). For all these reasons,
there is still a strong need to develop new, safe, and effective
antiviral compounds, possibly endowed with a newmechanism
of action (6). In this regard, the identification of the viral fac-
tors that regulate the very early virus-host cell interactions as
well as the functional characterization of the first viral proteins
expressed in infected cells, such as the pivotal immediate-early
2 (IE2) protein, may now provide a rationale for the design of
alternative antiviral strategies (7–9).
IE2 is an essential multifunctional protein that regulates cru-
cial events in the HCMV replication cycle, such as viral early (E)
gene activation, negative regulation of its own promoter, i.e., the
major immediate-early promoter (MIEP), induction of host cell
cycle progression, blocking of the cell cycle in S phase, and immu-
nomodulation (10). IE2 is a 579-amino-acid (aa) protein able to
dimerize, and its ability to self-interact has been related to its
DNA-binding activity (10–12). The C-terminal region of IE2
(from aa 195 to 579) is required and sufficient for transcriptional
activation, binding to DNA, dimerization, and protein-protein
interactions (12).
A major role of IE2 is the activation of viral E gene expression,
and this function is essential for the progression of the HCMV
replication cycle, since it cannot be substituted by the activities of
other viral or cellular proteins known so far (10). The DNA-bind-
ing activity of IE2 is required for maximal activation of the viral E
promoters and thus for the subsequent steps in the HCMV lytic
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cycle (10, 13). Although cellular RNA polymerase II and TATA-
binding protein (TBP) are recruited at viral E promoters in the
absence of IE2, its presence at responsive promoters such as these
is essential to achieve optimal E gene expression (13). Thus, it has
been suggested that IE2 regulates E gene transcription both by
direct binding to specificDNA sequenceswithin responsive E gene
promoters and by protein-protein interactions (10, 14).
When it accumulates in the infected cell, IE2 is also able to
repress its own promoter, i.e., the MIEP, to avoid toxic effects
related to its overexpression. This negative regulation occurs by
direct binding of IE2 to a sequence called the cis repression signal
(crs), which is located between the TATAbox and the IE transcrip-
tion start site (15–18). The crs regulatory element consists of a
14-bp A/T-rich region flanked on each side by two copies of a GC
dinucleotide (19). The binding of IE2 to crs physically blocks the
recruitment of RNApolymerase II and thus prevents the assembly
of the preinitiation complex and subsequent IE gene transcription
(20). Mutations in both crs and IE2 that impair the DNA-protein
interaction have an abortive effect on virus replication (21). Fur-
thermore, IE2 interacts with chromatin remodeling enzymes,
such as histone deacetylases, to facilitate viral replication and
regulate viral gene activation (22–25). In conclusion, IE2 is a
master regulator of HCMV gene expression, and its activities
are essential for the progression of the HCMV replication cycle
(10, 26).
Moreover, there is compelling evidence that the IE2 protein
plays a direct role in the pathogenesis of HCMV infection by in-
ducing a radical change in host gene expression that leads to alter-
ations in cell physiology and contributes to HCMV-induced cell
cycle alterations, immunomodulation, and blocking of the in-
flammatory response (10, 27–29). For example, IE2 stimulates the
expression of a set of genes involved in cell cycle progression, i.e.,
the E2F-responsive genes, thus providing HCMV with a mecha-
nism to overcome cellular quiescence in infected cells. In fact, on
one hand, IE2 promotes G0/G1 phase progression in infected qui-
escent cells, but on the other hand, in the same cells, it is also able
to block the cell cycle progression by arresting them in the S phase,
thus inhibiting cellular DNA synthesis in favor of viral DNA rep-
lication (10).
On the basis of this knowledge, it can be hypothesized that
molecules able to decrease IE2 expression or inhibit the effects of
its activity may be effective in blocking both HCMV replication
and the virus-induced pathological phenomena at a very early
stage of infection (7). In this scenario, inhibitors of IE2 might be
particularly important for the treatment of patients who do not
respond to the currently available inhibitors of viral DNA replica-
tion. To date, however, fewmolecules have been reported for their
ability to inhibit IE2 expression and/or its functions (7, 8). In this
regard, we have identified a 6-aminoquinolone (6-AQ) derivative
termed WC5, endowed with a specific anti-HCMV activity (30,
31). WC5 and some analogues have been demonstrated to inhibit
the IE2-induced transcriptional activation of two HCMV E gene
promoters, i.e.,UL112-113 andUL54, in a specific cell-based assay
(31–33).
In the present study, we characterized further the mechanism
of action ofWC5 by focusing on its effects on IE2. All together, the
results obtained suggest that the molecular mechanism whereby
WC5 exerts anti-HCMV activity relies on its ability to specifically
interfere with IE2-dependent regulation of viral responsive pro-
moters. Other IE2 activities that we have examined were not af-
fected byWC5. Interestingly, the inhibitory effect ofWC5was also
observed in the context of the regulation of themurine CMV early
E1 gene promoter by the immediate-early 3 protein (the murine
cytomegalovirus [MCMV] homolog of HCMV IE2), thus provid-
ing a rationale for further development of WC5 in vivo.
MATERIALS AND METHODS
Compounds. Compounds WC5 and WC5E were synthesized as previ-
ously described (30, 34) and solubilized in 100% dimethyl sulfoxide
(DMSO). GCV (Cymevene; Roche) was obtained from a prescription
pharmacy as a sodium salt.
Oligonucleotides. All oligonucleotides used for PCR, mutagenesis,
and sequencing, as well as the DNA probes for electrophoretic mobility
shift assays (EMSAs), were obtained from Life Technologies.
Plasmids.To create the pRSETB-IE2(290–579) plasmid, the sequence
of IE2 coding aa 290 to 579 was amplified from the pSGIE86 plasmid (35)
using primers IE2_290-579/FOR (5=-CAGTCAAGATCTTCGAGCCAC
CATGGGC-3=) and IE2_290-579/REV (5=-CACGTGGAATTCTTACTG
AGACTTGTTCCTC-3=) and cloned into the BglII/EcoRI sites of the
pRSETB plasmid (Life Technologies) downstream of the 6-histidine
(6His) tag. To generate the pGEX-2T-IE2(290–579) plasmid, the
IE2(290–579) fragment was subcloned from pRSETB-IE2(290–579) into
the BamHI/EcoRI sites of the pGEX-2T plasmid (GE Healthcare Life Sci-
ences) downstream of glutathione S-transferase (GST) coding sequence.
To generate the pGEX-2T-IE55DN290 plasmid, the C-terminal portion
of IE55 was amplified from the pSGIE55 plasmid (35) using primers
IE2_290-579/FOR and IE2_290-579/REV and cloned into the BamHI/
EcoRI sites of the pGEX-2T plasmid. To generate the pGEX-4T1-TBP
plasmid, the TBP coding sequence was subcloned from the pCR-TBP2/3
plasmid (36), previously obtained by PCR amplification of the TBP se-
quence from the pKB104 plasmid (kindly provided by A. J. Berk, Univer-
sity of California, Los Angeles [UCLA], CA), into the BamHI/SalI sites of
pGEX-4T1 (GE Healthcare Life Sciences) downstream of the GST coding
sequence. To generate pD15-PAplasmid, the polymerase acidic (PA) cod-
ing sequencewas amplified by PCR from the pcDNA-PAplasmid (fromP.
Digard, Roslin Institute, United Kingdom) using the PA-PD15/FOR and
PA-PD15/REV primers (5=-TTTAAACTCGAGATGGAAGATTTTGTG
CGAC-3= and 5=-AAAAAAACGCGTCTAACTCAATGCATGTGT-3=,
respectively) and cloned first into pCR2.1-TOPO vector (Life Technolo-
gies) and then the XhoI/MluI sites of pD15-UL44 vector (37). To create
the pMIEP crs wild-type (wt) reporter plasmid, the HCMV IE promoter-
enhancer sequence (positions 666 to 19 relative to the IE1/IE2 tran-
scription initiation site [GenBank accession no. K03104.1) was amplified
from the HCMV AD169 genome by PCR using the MIEP wild-type (wt)
primer set (FOR, 5=-ACTGATGCTAGCGCATACGTTGTATCCATAT
C-3=, and REV, 5=-AGTGATAAGCTTGCGTCTCCAGGCGAT-3=; the
underlined letters are the NheI andHindIII restriction sites used for clon-
ing, respectively). The PCR fragments were cloned into the pGL3-basic
vector (Promega) to obtain the pMIEP crs wt construct. To generate its
derivative pMIEP crs mut (mutated), the crs element (from 14 to 1
with respect to the IE1/IE2 transcription initiation site) of pMIEP crs wt
was changed, with the insertion of a unique restriction site (StuI,13 to
7) with the QuikChange XL kit (Stratagene), using the crsmut oligonu-
cleotide set (FOR, 5=-GTCTATATAAGCAGAGCTgaggcctgtccacGTCA
GATCGCCTGGAGAC-3=, and REV, 5=-GTCTCCAGGCGATCTGACca
tggacaggcctcTGCTCTGCTTATATAGAC-3=; the lowercase bold-type
letters indicate mutated nucleotides), giving the pMIEP crsmut plasmid.
Plasmids pSGIE86-P535A/Y537A and pSGIE86-H446A/H452A for eu-
karyotic expression of the corresponding mutant IE2 proteins were ob-
tained by introducing desired point mutations in the pSGIE86 plasmid
(35) with the QuikChange XL kit and the IE2 P535A/Y537A and IE2
H446A/H452A primer set, respectively (13). Plasmids pE(207)Luc and
pME(207)Luc containing the firefly luciferase reporter gene under the
control of wt and mutated cellular cyclin E promoters, respectively, were
kindly provided by E. A. Thompson (Mayo Clinic Florida, FL) and were
Mercorelli et al.
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previously described (38). The pUL54-luciferase indicator plasmids
pUL54-0.4, pUL54-0.3, pUL54-0.15, and pUL54-0.15 IR-1mut were gen-
erated as previously described (39). The pRL-SV40 vector expressing Re-
nilla luciferase was from Promega. For the construction of the murine
CMV (MCMV) pE1 reporter plasmid, pE1CAT (40) was digested on the
BglII and HindIII restriction sites to obtain a 1,829-bp fragment that
contains the MCMV E1 promoter responsive for IE3 transactivation ac-
tivity (41). This fragment was cloned into the corresponding sites of the
pGL3-basic vector (Promega) to obtain the pE1 construct. pIE3, which
contains the coding sequence of MCMV IE3 gene, was described previ-
ously (40).
Recombinant protein expression andpurification.The recombinant
6His-IE2(290–579) protein (6His-IE2DN290) was purified from Esche-
richia coli BL21(DE3)pLysS strain harboring the pRSETB-IE2(290–579)
plasmid, according to the protocol previously described for the 6His-PA
protein (42). The recombinant proteins GST, GST-IE2D290, and GST-
TBP were purified from E. coli BL21(DE3)pLysS harboring the pGEX-2T,
pGEX-2T-IE2(290–579), and pGEX-4T1-TBP plasmids, respectively, ac-
cording to the protocol previously described for GST-Ubc9 (43). The
recombinant proteins GST-IE55DN290 and GST-PA were purified from
E. coli BL21(DE3)pLysS harboring the pGEX-2T-IE55DN290 and
pD15-PA plasmids, respectively, according to the protocol previously de-
scribed for GST-UL44 (37).
GST pulldown assays. For the GST pulldown assays, 0.03 nmol of
either GST, GST-IE2DN290, GST-IE55DN290, GST-TBP, or GST-PA fu-
sion proteinwas incubated for 2 h at 4°Cwith 0.6 nmol of 6His-IE2DN290
in a final volumeof 0.1ml in binding buffer (25mMHEPES [pH7.5], 12.5
mMMgCl2, 20% glycerol, 0.1%NP-40, 150 mMKCl, 0.15 mg/ml bovine
serum albumin [BSA], and 1mMdithiothreitol [DTT]) in the presence of
either 0.2% DMSO, 50 MWC5, or 50 MWC5E. After incubation, the
samples were loaded onto 0.1 ml of glutathione-Sepharose columns. The
columns were then washed with 2 ml of NETN buffer (20 mM Tris-HCl
[pH 7.5], 100 mMNaCl, 0.1 mM EDTA, and 0.5% NP-40), and fractions
of 0.1 ml of the wash samples were collected (only samples derived from
the last wash fraction were analyzed). The bound complexes were eluted
with 0.3 ml of elution buffer (NETN plus 15 mM glutathione). The sam-
ples derived from the input, wash, and eluted fractions were then analyzed
by Western blotting using a mouse monoclonal antibody (MAb) anti-
6His tag (clone His-1, 1:1,000 dilution; Sigma). Immunocomplexes were
detected with goat anti-mouse immunoglobulin Ab conjugated to horse-
radish peroxidase (HRP) (1:2,000 dilution; Santa Cruz Biotech) and visu-
alized by enhanced chemiluminescence (LiteAblot Extend long-lasting
chemiluminescent substrate kit; EuroClone).
Cells and virus.Human embryonic kidney (HEK) 293 andU373-MG
cells were grown in Dulbecco modified Eagle’s medium (DMEM) (Life
Technologies) supplemented with 10% fetal bovine serum (FBS) (Life
Technologies), 100 U/ml penicillin, and 100 g/ml streptomycin sulfate
(P/S) (both from Life Technologies). NIH 3T3 cells were grown as mono-
layers inDMEMsupplementedwith 10%donor bovine serum (Life Tech-
nologies), 2 mM glutamine, and P/S. Low-passage human embryonic
lungfibroblasts (HELFs)were grown inEagle’sminimal essentialmedium
(MEM) (Life Technologies) supplemented with 10% FBS, 1 mM sodium
pyruvate, 2 mM glutamine, and P/S. Quiescent HELF cells (arrested in
G0/G1 phase) were obtained by culturing subconfluent monolayers for 1
week in medium containing 0.5% FBS (low-serum medium). Flow cy-
tometry demonstrated that 90% of the cells were growth arrested.
HCMV strain AD169 (VR-538) was purchased from the American Type
Culture Collection (ATCC) (Manassas, VA).
Recombinant adenovirus vectors. To create the pAC-CMV IE2 ade-
novirus shuttle vector, the pSGIE86 plasmid was digested with EcoRI and
XbaI, and the cDNA of the HCMV IE2 protein was subsequently cloned
into the corresponding sites of pAC-CMV (44). To generate a recombi-
nant adenovirus expressing the HCMV IE2 protein (AdV-IE2), the pAC-
CMV IE2 and pJM17 vectors (Microbix Biosystems) were cotransfected
into subconfluent HEK 293 cells using the CaPO4-DNA coprecipitation
method. Recombinant AdV-IE2 was then identified by immunoblotting.
After several rounds of plaque purification, recombinant AdV-IE2 was
amplified on HEK 293 cells. A recombinant adenovirus expressing the E.
coli -galactosidase gene (AdV-LacZ) was used as a control (45).
Immunoblotting. Whole-cell protein extracts of AdV-IE2-infected
cells were prepared as previously described (46), separated by 10% SDS-
PAGE, and then analyzed by Western blotting with a mouse anti-HCMV
IE antigenMAb (clone E13; Argene Biosoft) and amouse anti-actinMAb
(1:2,000 dilution; Chemicon International) used as a control for protein
loading. Immunocomplexes were detected with a sheep anti-mouse im-
munoglobulin Ab conjugated to HRP (1:2,000 dilution; Amersham).
Cell transfections andadenoviral transductions.For the transfection
experiments with U373-MG cells, the cells were seeded in 24-well plates
and the next day were transiently cotransfected using calcium phosphate
(CellPhect transfection kit; GE Healthcare) with 0.05 g of pMIEP crs wt
or mut plasmid and, where indicated, 1 g of wt or mutated pSGIE86
plasmid in a 1:5 ratio, as well as 0.05g of pRL-SV40 plasmid as a control
for transfection efficiency. The total DNA amount was equalized with
pSG5 empty vector (Promega). After incubation for 4 h at 37°C, the trans-
fection mixtures were removed, and medium containing either 50 M
WC5orWC5E, orDMSO (0.2%) as a control, was added to the cells. At 48
h posttransfection, the cells were harvested, and both the firefly luciferase
andRenilla luciferase activities weremeasured by a luciferase assay system
and a Renilla luciferase assay system (Promega), according to the manu-
facturer’s instructions. For the transfection/transduction experiments
with HELF cells, they were grown on 24-well plates and cotransfected
using SuperFect reagent (Qiagen) with 0.9 g of each pUL54-derived
plasmid andwith 0.1g of pRL-SV40plasmid as an internal control. At 24
h posttransfection, the cells were infected with either AdV-IE2 or AdV-
LacZ at a multiplicity of infection (MOI) of 10 for 2 h at 37°C and then
treated with 50 MWC5, 50 MWC5E, or 0.2% DMSO as a control. At
48 h postransduction, the cells were harvested, and the firefly luciferase
and Renilla luciferase activities were measured. For all the experiments,
the values were normalized by dividing the values obtained for firefly
luciferase by the values obtained for Renilla luciferase and expressed as
relative luciferase units (RLU).
Real-time RT-PCR. Quiescent HELFs were infected with HCMV
(MOI, 0.5 PFU/cell) or with AdV-IE2 or AdV-LacZ (MOI, 10 PFU/cell),
and, where indicated, they were treated 2 h postinfection (p.i.) with 50
MWC5 orWC5E. At 48 h p.i., the total cellular RNAwas extracted with
the NucleoSpin RNA kit (Macherey-Nagel). One microgram of RNA was
then retrotranscribed using the RevertAid H Minus FirstStrand cDNA
synthesis kit (Fermentas) in a final volume of 20 l. Two microliters of
cDNAs (or water as a control) was amplified in duplicate by quantitative
PCR (qPCR) using the Brilliant SYBR green QPCR master mix (Strat-
agene) in a final volume of 25 l. The sequences of the oligonucleotides
used for assessing mRNA levels were as follows: TS (FOR, 5=-GCAAAGA
GTGATTGACACCATCAA-3=, and REV, 5=-CAGAGGAAGATCTCTTG
GATTCCAA-3=), CDK2 (FOR, 5=-GCTAGCAGACTTTGGACTAGCCA
G-3=, and REV, 5=-AGCTCGGTACCACAGGGTCA-3=), RR1 (FOR, 5=-G
GAGGAATTGGTGTTGCTGT-3=, and REV, 5=-GCTGCTCTTCCTTTCCT
GTG), and -actin (FOR, 5=-CAAAAGCCTTCATACATCTC-3=, and
REV, 5=-TCATGTTTGAGACCTTCAA-3=) as an internal control gene for
the normalization data. Following an initial denaturing step at 95°C for 2
min to activate 0.75 units of PlatinumTaqDNApolymerase (Invitrogen),
the cDNAs were amplified for 30 cycles of 95°C for 1 min, 58°C for 1 min,
and 72°C for 1 min. For quantitative analysis, the log change in fluores-
cence was plotted against the cycle number, and a thresholdwas set for the
changes in fluorescence at a point in the linear PCR amplification phase
(threshold cycle [CT]). TheCT values for each genewere normalized to the
CT values for -actin using the CT equation. The level of target RNA,
normalized to the endogenous -actin reference and relative to the 12-h
infected cells, was calculated by the comparative CT method and the
2CT equation.
Mechanism of Action of WC5 against HCMV IE2 Protein
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Electrophoretic mobility shift assays. To generate the crs-derived
probes, single-stranded forward and reverse oligonucleotides containing
wt crs sequences (FOR, 5=-GCTGAGCTCGTTTAGTGAACCGTCA-3=,
and REV, 5=-GATCTGACGGTTCACTAAACGAGCT-3=; the italic up-
percase characters indicate the wt crs sequence) or mutated (mut) crs
sequences (FOR, 5=-GCTGAGCTgagggcctgtccaCGTCA-3=, and REV, 5=-
GATCTGACGtggacaggcctcAGCT-3=; the mutated nucleotides inmut crs
are lowercase bold-type letters, and the italic uppercase characters indi-
cate the wt crs sequence) were annealed by incubating 500 pmol of each
complementary strand in 10 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, and
50 mM NaCl for 5 min at 95°C, followed by gradual cooling at room
temperature (RT). For the EMSAs, 2.5g of purified 6His-IE2DN290was
incubated at 20°C for 20min in a final volume of 20l in Tris-EDTA (TE)
buffer (pH 8.0) containing 10% glycerol, 3g/l BSA, 1 mMMgCl2, 12.5
ng/l poly(dA)-oligo(dT), 5 ng/l sonicated and denatured salmon
sperm DNA (Sigma), 0.1 mM DTT, 100 mM KCl, and 25 pmol of the
double-stranded crs-derived probes. Test 6-AQs (0.5 mM) were added to
the reaction products where indicated, and control reactions with 0.2%
DMSO were included. After incubation, the reaction mixtures were sep-
arated on a native 5% polyacrylamide gel in 0.5 TBE buffer (90 mM
Tris-borate, 2 mM EDTA [pH 8.0]) at 4°C, followed by staining with
GelRed (Biotium, Inc.), according to the manufacturer’s protocol. For
EMSAs using the sequence derived from the cellular cyclin E promoter,
the same protocol was used but with the following annealed oligonucleo-
tide sequences for cellular cyclin E (CcnE): FOR, 5=-AGCCGGCGCGGC
CGCCAGCGCGGTGT-3=, and REV, 5=-ACACCGCGCTGGCGGCCGC
GCCGGCT-3=.
Statistical analysis. All statistical tests were performed using the
GraphPad Prism software. The data are presented as the means 	 stan-
dard deviations (SD). The data were analyzed for significance using a
paired t test and were considered statistically significant at a P value of
0.05.
RESULTS
WC5 does not affect IE2 dimerization and its interaction with
TBP.We previously observed that WC5 interferes with the trans-
activating activity of IE2 on two HCMV E gene promoters (31).
Since IE2 regulates gene expression by both protein-protein inter-
actions and direct binding to specific DNA sequences within E-re-
sponsive promoters (10), we first wished to determinewhether the
inhibitory effect of WC5 might be due to interference with two
protein-protein interactions that are required for the transactivat-
ing activity of IE2, such as the interaction with itself and with
cellular TBP. To this end, the GST pulldown assays were set up
with a truncated formof IE2, IE2DN290, which has been shown to
be sufficient for both dimerization and interaction with TBP (12,
47) and which was fused to either to GST or a 6His tag. The puri-
fied recombinant GST-IE2DN290 and 6His-IE2DN290 proteins
were mixed, incubated in the absence or presence of WC5 or its
inactive derivative WC5E as a control (30), and then tested for
dimerization by the GST pulldown assays. As shown in Fig. 1A
(left), the dimerization between the two differently tagged ver-
sions of the C-terminal segment of IE2 occurred independently of
the presence of WC5 or WC5E, since bands corresponding to
6His-IE2DN290 were detected in the eluted fraction of each reac-
tion mixture. A control reaction in which 6His-IE2DN290 was
incubated with either GST alone or GST fused to a truncated form
of IE2 that is dimerization defective, i.e., GST-IE55DN290 (11),
ruled out the possibility that the presence of 6His-IE2DN290 in
the eluted samples was due to nonspecific interactions (Fig. 1A,
right).
Since the interaction of IE2 with TBP has been reported to be
critical for its transactivating activity (48), we next investigated
whether WC5 and WC5E may affect the interaction between
6His-IE2DN290 and a GST-TBP fusion protein. As shown in Fig.
1B (left), both compounds did not exert any effect on the interac-
tion between 6His-IE2DN290 and GST-TBP. Furthermore, to
confirm that the presence of 6His-IE2DN290 in the eluted sam-
ples was due to specific interaction with TBP, we included control
reactions with either GST alone or an unrelated GST fusion pro-
tein, such as GST-PA, which contains the PA protein of influenza
virus. As shown in Fig. 1B (right), no interaction was detected
under these conditions. Taken together, these results indicate that
WC5 does not affect the ability of IE2 to interact with itself or with
TBP, thus excluding the possibility that its inhibitory activity is
due to interference with these protein-protein interactions.
WC5 does not affect the IE2-dependent stimulation of some
cellular responsive genes. The observation that WC5 does not
FIG 1 WC5 does not affect IE2 protein-protein interactions. (A) GST pulldown assays performed with 6His-IE2DN290 and GST-IE2DN290 recombinant
proteins in the absence or presence of WC5 or WC5E (left). As a control of specificity, reactions with either GST alone or GST-IE55DN290 were also included
(right). (B) GST pulldown assays performed with 6His-IE2DN290 and GST-TBP in the absence or presence of either WC5 or WC5E (left). As a control of
specificity, reactions with either GST alone or GST-PA were also included (right). The input (I), the last wash fraction (W), and eluted (E) proteins of each
reactionmixture were visualized byWestern blotting with an anti-6His antibody. The positions of the molecular mass markers (in kilodaltons) are indicated on
the left side of each panel.
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inhibit IE2 dimerization and its interactionwithTBPprompted us
to investigate whetherWC5might interfere with the protein-pro-
tein interactions that are related to IE2-dependent regulation of
cellular gene expression. Thus, we tested the effect of WC5 on the
expression of a set of selected E2F-dependent cellular genes whose
transcription has been reported to be stimulated either by HCMV
infection or upon expression of IE2 alone and that are thought to
be regulated by IE2 via protein-protein interactions rather than by
the direct binding of IE2 to their promoters (49, 50). To this end,
the mRNA levels of the genes encoding cellular thymidylate syn-
thetase (TS), cyclin-dependent kinase 2 (CDK2), and ribonucle-
otide reductase 1 (RR1) were measured by real-time reverse tran-
scription-PCR (RT-PCR) in quiescent HELFs that had been
infected with HCMV for 48 h in the absence or presence of WC5
or its inactive derivative WC5E as a control. As shown in Fig. 2A,
HCMV infection, as is known, increased the mRNA levels of TS,
CDK2, and RR1. However, WC5 did not significantly affect the
accumulation of these HCMV-stimulated cellular mRNAs.
Next, we evaluated the effect of WC5 on the expression of the
abovementioned HCMV-responsive genes when stimulated by
IE2 alone. Quiescent HELFs were infected with either an IE2-
expressing adenoviral vector (AdV-IE2) or a -galactosidase-ex-
pressing adenovirus (AdV-LacZ) as a control. The successful ex-
pression of transduced exogenous IE2 protein was assessed by
immunoblotting analysis (Fig. 2B). IE2- or LacZ-expressing
HELFs were then treated with WC5 or WC5E, and at 48 h after
drug exposure, themRNA levels of the target genesweremeasured
by real-time RT-PCR. As expected, in the AdV-IE2-transduced
cells, a significant increase in TS, CDK2, and RR1 mRNA levels
was measured, which was not observed in the cells transduced
with the control AdV-LacZ (Fig. 2C). In keeping with the results
obtained in the HCMV-infected HELFs, the increase in mRNA
levels stimulated by IE2 overexpression was not affected by WC5
or WC5E (Fig. 2C).
Taken together, these results indicate thatWC5 does not affect
the IE2-mediated expression of representative IE2-responsive cel-
lular genes.
WC5 abrogates the IE2-dependent repression of HCMV
MIEP. The observation that WC5 does not tamper with the IE2-
dependent gene regulation via protein-protein interactions led us
to examine whether the DNA binding of IE2 to a responsive pro-
moter might represent a target of WC5. To this end, we took into
account the IE2-dependent repression of its own promoter, i.e.,
the MIEP, which depends on the direct interaction between IE2
and the crs sequence (10). To investigate the effect of WC5 on the
IE2-mediated negative regulation of MIEP, permissive U373-MG
cells were cotransfected with a plasmid containing the luciferase
reporter gene under the control of MIEPs bearing either the wt or
a mutated (mut) crs sequence (designated pMIEP crs wt and
pMIEP crsmut, respectively) andwith a plasmid expressingwt IE2
(pSGIE86). As expected (13), IE2 expression caused a 
5-fold
reduction in MIEP transcriptional activity in cells cotransfected
with pMIEP crswt (Fig. 3A). The lack of a significant reduction in
luciferase expression in the extracts prepared from cells that had
FIG 2 WC5 does not affect the HCMV- or IE2-dependent stimulation of cellular E2F-responsive genes. (A) Growth-arrested HELFs were infected with HCMV
at anMOI of 0.5 PFU/cell or weremock infected (mock) and, where indicated, treatedwithWC5orWC5E. Total cellular RNAwas isolated at 48 h p.i. and reverse
transcribed. qPCR was then carried out with the appropriate primers for cyclin-dependent kinase 2 (CDK2), thymidylate synthetase (TS), ribonucleotide
reductase 1 (RR1), and -actin (as a control). Next, the RNA levels were normalized according to the expression of the -actin gene. (B) Expression of the IE2
protein in HELFs transduced with a recombinant AdV-IE2. The HELFs were infected with AdV-IE2 (MOI, 10 PFU/cell) or mock infected (mock). At the
indicated times p.i., the total cell extracts were analyzed by immunoblotting with an anti-IE2 antibody. -Actin immunodetected with an MAb served as an
internal control. (C) Effects of WC5 orWC5E on cellular E2F-responsive genes in IE2-expressing quiescent HELFs. The total RNA was isolated at 48 h p.i. from
quiescent HELFs that had not been infected (mock) or had been infected with AdV-IE2 or AdV-LacZ at an MOI of 10 PFU/cell and treated as described above.
The RNA levels were then analyzed by qPCR and normalized to -actin as an endogenous control. (A and C) Reported RNA relative expression levels are
normalized to the values of the mock-infected cells, which were set at a value of 1. The data shown are the means	 SD from three independent experiments.
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been cotransfectedwith the pMIEP crsmut plasmid confirmed the
specificity of the observed IE2-dependent repression (Fig. 3A).
However, when the transfected cells were treated with WC5, the
luciferase expression was restored to levels comparable to those
observed in the absence of IE2 expression only in cells transfected
with wt crs-containing plasmid but not in cells transfected with
pMIEP crsmut (Fig. 3A). As expected, the inactive WC5E did not
exert any effect on IE2-mediated repression of MIEP (Fig. 3A).
Moreover, the effect of WC5 onMIEP repression by IE2 was dose
dependent (see Fig. S1 in the supplemental material available at
http://www.medicinamolecolare.unipd.it/sites/dipartimenti.it
/files/Supplemental%20Material.pdf), thus further indicating a
specific effect for IE2-crs interaction. To confirm these results, we
tested two mutated versions of the IE2 protein for their ability to
repress the MIEP in the presence of WC5. The first mutant pro-
tein, bearing the P535A/Y537A substitutions, is competent for
MIEP repression but is no longer able to transactivate viral E gene
promoters (13). The second mutant, with H446A/H452A substi-
tutions, is not able to repress the MIEP or transactivate viral E
promoters (13). As shown in Fig. 3B, the repressive activity of IE2
P535A/Y537A on MIEP was inhibited by WC5 but not by the
inactive analogWC5E. In contrast, no effect ofWC5orWC5Ewas
observed in the cells cotransfected with MIEP crs wt and with a
plasmid expressing the IE2 H446A/H452A protein (Fig. 3B).
Thus, these results further indicate that WC5 specifically inter-
feres with the IE2-dependent repression of MIEP.
To support further this observation, we then analyzed the ef-
fect of WC5 and of WC5E as a control on the ability of the C-ter-
minal fragment of IE2 (aa 290 to 579), which has been shown to be
sufficient forDNAbinding (10, 12, 47, 51), to interact in vitrowith
awt crs-derived probe. The IE2C-terminal segmentwas expressed
as the recombinant 6His-IE2DN290 protein. As shown in Fig. 4A,
in the EMSAs, a shifted protein-probe complex was observed
when the 6His-IE2DN290 protein was incubated with wt crs (lane
4). This complex was not detected when amutated crswas used as
a probe, thus demonstrating the specificity of IE2 binding (Fig. 4B,
lane 4). The addition ofWC5 to either wt or mut crs alone did not
produce any effect on the mobility of the probes (compare lane 2
to lane 3 in both Fig. 4A and B). In contrast, the presence of WC5
in the reaction mixture containing 6His-IE2DN290 and wt crs
prevented the formation of the protein-probe shifted complex
(Fig. 4A, lane 7), thus indicating thatWC5 is able to interfere with
the binding of IE2 to wt crs. The inability of WC5E to interfere
with the formation of the IE2DN290-crs complex confirmed that
the inhibition exerted by WC5 was specific (Fig. 4A, lane 6). As
further specificity controls, EMSAs with the DNA-binding defec-
tive GST-IE55DN290 protein (11) and either wt ormut crs probes
were performed. In these samples, the protein-probe complex was
FIG 3 WC5 abrogates the IE2-mediated repression of MIEP. (A) U373-MG cells were transfected with a luciferase reporter plasmid containing HCMV MIEP
(pMIEP-crs) with either wild-type (wt) or mutated (mut) crs or cotransfected with an IE2-expressing plasmid (pSGIE86) and then treated with 0.2% DMSO or
50MWC5 orWC5E. (B) U373-MG cells were cotransfected with theMIEP-crswt plasmid and plasmids expressingmutant P535A/Y537A andH446A/H452A
IE2 proteins and then treated with 0.2% DMSO or 50 MWC5 or WC5E. (A and B) Transfection mixtures also contained a plasmid constitutively expressing
Renilla luciferase to normalize variations in transfection efficiency. The reported values represent the means 	 SD from three independent experiments in
duplicate and are expressed as relative luciferase units (RLU) (i.e., light units of firefly luciferase per 104 Renilla luciferase light units as determined at 48 h
posttransfection); *, P 0.05, and ***, P 0.001, versus calibrator sample (pMIEP crs wt or mut plus pSGIE86 wt or mut plus DMSO).
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not detected independently of the presence ofWC5 (lane 5 in both
Fig. 4A and B).
Taken together, the results of this section indicated that WC5
abrogates the IE2-mediated repression of MIEP and prevents the
binding of IE2 to the crs element. Thus, in the context of the
HCMV replicative cycle, WC5, besides inhibiting the IE2-depen-
dent transactivation of two E promoters, i.e., the UL54 and
UL112-113 promoters (31), also interferes with another essential
function of IE2, such as the negative regulation of MIEP.
Aproximal 150-bp segment is sufficient tomediate theWC5-
dependent inhibition of HCMVUL54 gene promoter transacti-
vation. We previously observed that WC5 is able to inhibit the
IE2-dependent transactivation of two E genes of HCMV, i.e.,
UL112-113 and UL54, both in transfected cells and in the context
of viral infection (31). Thus, to gain further insights into the
mechanism of this inhibitory activity, we wished to identify the
minimal portion of an E gene promoter activated by IE2 still sen-
sitive to WC5 inhibition. To this end, the promoter of the UL54
gene, an essential HCMV gene that encodes the DNA polymerase
catalytic subunit, was chosen as a prototypic E gene promoter.
Luciferase reporter plasmids containingUL54 gene promoter seg-
ments (pUL54) with progressive 5= deletions (thus leaving ap-
proximately 0.4, 0.3, and 0.15 kbp upstream from the transcrip-
tion start site; Fig. 5) were therefore generated (39). The HELF
cells were transfected with the different pUL54 constructs and
then infected with either AdV-IE2 or AdV-LacZ as a control. After
transduction with recombinant AdVs, the cells were finally incu-
bated in the absence or presence of WC5 or WC5E. As shown in
Fig. 5, IE2 expression transactivated all three pUL54-derived con-
structs, although at different levels: from about 12-fold for
pUL54-0.4 up to30-fold for pUL54-0.15. Treatment withWC5
but not WC5E reduced the transcriptional activities of all the
tested reporter constructs, including the shortest pUL54-0.15
construct,3-fold.
The UL54 gene promoter contains an 8-bp inverted repeat el-
ement 1 (IR-1) located between 54 and 43 nucleotides (nt)
relative to the transcription start site, which has been shown to be
required for both HCMV- and IE2-mediated transactivation (52,
53). IE2 and the cellular transcription factor Sp1 have been found
in an IR-1 DNA-protein complex detected in IE2-overexpressing
cells (54). In addition, it was demonstrated that IR-1 contains an
unconventional binding site for the cellular transcription factor
Sp1, which seems to play a role in UL54 gene promoter basal
activity in both IE2-transfected cells and HCMV-infected cells
(54, 55). To investigate the involvement of the IR-1 element in
FIG 4 WC5 inhibits the binding of IE2 to the MIEP crs wt element. Electropho-
reticmobility shift assays (EMSAs)were performed to evaluate the effects ofWC5
and WC5E on the IE2DN290-crs interaction by incubating the 6His-IE2DN290
proteinwithMIEP crs-containingprobeseitherwt (A)ormutated(mut) (B) in the
absence or presence ofWC5andWC5E.The binding reactionproductswere then
resolved on 5% native polyacrylamide gels and stained with GelRed. The down-
facing arrow indicates the absence of the protein-probe complex in the presence
ofWC5.
FIG5 A150-bpsegmentof theUL54genepromoter is sufficient tomediate the inhibitory effectofWC5onIE2-dependent transactivation.HELFswere transfectedwith
luciferase reporter plasmids containing segments ofHCMVUL54promoter progressively deleted from the 5= end and/ormutated in the IR-1 element and subsequently
infected with AdV-IE2 or AdV-LacZ at an MOI of 10 PFU/cell. Where indicated, the cells were treated with 0.2% DMSO, WC5, or WC5E. At 48 h p.i., luciferase
expression was determined. The transcriptional activity of each indicator construct is expressed in relative luciferase units (RLU). The data shown are the means	
standard error of the mean from three independent experiments; **, P 0.01, and ***, P 0.001, versus the calibrator sample (AdV-IE2 plus DMSO).
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WC5-mediated inhibition of IE2 transactivation, a luciferase re-
porter construct driven by the minimal UL54 promoter mutated
in the IR-1 element (pUL54-0.15 IR-1mut) was generated and
examined in the transfection/transduction experiments. As shown in
Fig. 5, and in accordance with previous observations (54, 55),
inactivation of the IR-1 element caused about a 3-fold decrease in
the IE2-mediated UL54 promoter transactivation compared to
that of pUL54-0.15, which confirmed the prominent role of IR-1
in the regulation of the overall UL54 gene promoter response to
IE2 (52).Despite the lack of a functional IR-1 element, IE2was still
able to transactivate the pUL54-0.15 IR-1mut construct about
9-fold, and this IE2-dependent transactivation was reduced by
WC5 treatment by60% (Fig. 5). Similar results were obtained in
another experimental setting, i.e., U373-MG cells that had been
transfected with the pUL54 indicator constructs together with an
IE2-expressing plasmid (pSGIE86) and then treated with WC5
and WC5E (data not shown).
All together, these results indicate that a segment of 150 bp
upstream from the UL54 transcription initiation site is sufficient
to mediate the inhibitory activity of WC5 on the IE2-dependent
transactivation of the UL54 promoter, and that WC5 retains its
ability to downregulate IE2-mediated transactivation in the ab-
sence of a functional IR-1 element.
WC5does not affect the IE2-dependent activation of cellular
cyclin E promoter. The ability of WC5 to interfere with the bind-
ing of IE2 to viral promoters led us to investigate whether the
transactivation of a cellular gene regulated by IE2 via direct bind-
ing to its promoter, such as cyclin E, might be a target of WC5.
Cellular cyclin E (CcnE) is upregulated upon HCMV infection in
quiescent cells to promote G0/G1 transition (56), and its expres-
sion can be directly stimulated by IE2 (38). To assess the effect of
WC5 on the IE2-mediated transactivation of the CcnE promoter,
we transfectedHELFs with reporter constructs containing either a
portion of the wt CcnE promoter, as in pE(207)Luc (which in-
cludes nucleotides207 to77 of the humanCcnEpromoter), or
a mutated version wherein the binding sites for the cellular tran-
scription factor E2F at 16 and 7 have been mutated, as in
pME(207)Luc (38). The transfected cells were then infected
with AdV-IE2 or AdV-LacZ as a control and treated withWC5 or
WC5E. As shown in Fig. 6A, the expression of the IE2 protein
transactivated the wt CcnE promoter, and the disruption of E2F
binding sites in pME(207)Luc did not affect the IE2-dependent
transactivation of the cyclin E promoter, as previously reported
(38). The addition of WC5 did not produce any effect on the
IE2-dependent transactivation of the CcnE promoter indepen-
dently of the presence of mutations in the E2F binding sites (Fig.
6A). Similar results were obtained with U373-MG cells that had
been transfected with the CcnE promoter-derived reporter plas-
mids together with an IE2-expressing plasmid and then treated
with WC5 or WC5E (data not shown). In addition, we investi-
gated the effect of WC5 on the binding of the 6His-IE2DN290
protein to the CcnE promoter-derived probe corresponding to
FIG 6 WC5 does not affect the binding of IE2 to the cellular cyclin E promoter. (A) HELF cells were transfected with a luciferase reporter plasmid containing
either the wt [pE(207)Luc] or mutated [pME(207)Luc] cellular cyclin E promoter and subsequently infected with AdV-IE2 or AdV-LacZ at an MOI of 10
PFU/cell. The cells were treated with 0.2%DMSOor 50MWC5 orWC5E. At 48 h p.i., luciferase expression was determined and expressed as relative luciferase
units (RLU). The reported values represent the means	 SD from three independent experiments in duplicate. (B) EMSA performed to evaluate the effects of
WC5 andWC5E on the interaction of IE2DN290 with a cyclin E promoter-derived probe (CcnE). The down-facing arrow indicates the absence of any effect of
WC5 on the mobility of the protein-probe complex compared to Fig. 4A, lane 7.
Mercorelli et al.
6622 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 O
ctober 23, 2014 by DIP DI SANITA PUBBLICA E M
ICRO
BIO
LO
G
IA
http://aac.asm
.org/
D
ow
nloaded from
 
35 to60 nucleotides that were previously reported to interact
with IE2 (38). As expected, a probe-protein complexwas observed
when 6His-IE2DN290 was incubated with a CcnE probe (Fig. 6B,
lane 2). However, according to the results obtained from the
transfection experiments, WC5 and WC5E did not affect the for-
mation of the shifted protein-probe complex (Fig. 6B, lanes 3 and
4). Together, these data indicate thatWC5 does not interfere with
the binding of IE2 to the CcnE promoter.
WC5 inhibits the IE3-dependent transactivationof anEgene
of murine CMV. We previously reported that WC5 was active
against murine cytomegalovirus (MCMV) replication in vitro
(30). Since MCMV represents a suitable model for in vivo studies
for validating the potential use in the prevention and/or control of
HCMV infection of in vitro-selected anti-HCMV agents (57), we
next investigated whetherWC5may also affect the transcriptional
activation of an E gene of MCMV. The MCMV genome encodes
anHCMV IE2 homolog, the IE3 protein, which has been shown to
be required for the transactivation of viral E and L genes and thus
for the progression of theMCMV replicative cycle (40, 58–60). To
analyze the effects of WC5 on IE3-mediated E gene transactiva-
tion, an indicator construct driven by the promoter of the proto-
type early E1 gene of MCMV (pE1-Luc) was generated and trans-
fected into NIH 3T3 cells, together with an IE3-expressing
plasmid in the absence or presence of WC5 or GCV. As shown in
Fig. 7, the expression of the IE3 protein strongly transactivated the
E1 promoter. WC5 treatment inhibited the reporter gene expres-
sion about 3-fold compared to that of the untreated samples. The
absence of an inhibitory effect in the transfected cells treated with
either the inactive analog WC5E or GCV indicated the specificity
of the WC5 effect on the IE3-mediated transactivation of pE1.
These results suggest that the mechanism of action of WC5
against bothHCMV andMCMVmight be conserved and, impor-
tantly, demonstrates that MCMV infection is a valid preclinical
model for the study of the antiviral activity of WC5 in vivo.
DISCUSSION
The currently available anti-HCMV drugs have several draw-
backs; in addition, they cannot prevent the reactivation of latent
viral infection and are not approved for the treatment of congen-
ital infections. The identification of novel anti-HCMV agents that
can block IE gene expression and/or IE functions at very early
stages without causingmajor adverse effectsmay provide an alter-
native strategy for inhibitingHCMV reactivation, replication, and
immunopathogenesis (7, 8). The feasibility of this approach has
been validated by fomivirsen, a 21-base phosphorothioate oli-
godeoxynucleotide complementary to IE2mRNAand thus able to
block IE2 protein expression, which has been approved for intra-
ocular application in patients with HCMV retinitis (2).
To contribute to the characterization and development of new
IE2-targeting molecules, this study was undertaken to investigate
further the mechanism of action of the 6-aminoquinolone WC5
against HCMV IE2.We previously demonstrated thatWC5 inter-
feres with the IE2-mediated transactivation of two HCMV E gene
promoters, i.e., the UL112-113 and UL54 promoters, in a specific
cell-based assay (31). Here, we have examined whether other
functions of IE2 might be affected by WC5 by focusing on some
known interactions of IE2 with DNA and proteins that contribute
to viral replication. We demonstrated that WC5 interferes with
some functions of IE2 that are essential for productive HCMV
replication, i.e., the autoregulation of MIEP and the transactiva-
tion of viral E genes that are required for the progression of the
HCMVreplicative cycle (10, 21), while it has no effect on other IE2
activities (e.g., the upregulation of some cellular genes).
First, we analyzed the effects of WC5 on those IE2 protein-
protein interactions that have been shown to be relevant for its
autoregulatory activity and are involved in the IE2-mediated
transactivation of viral E promoters, such as dimerization or in-
teraction with TBP. IE2 interacts with itself (10, 12) and with the
C-terminal basic repeat domain of TBP (10, 14) through domains
that are overlapping and locatedwithin the C-terminal segment of
the protein. The same domains are required also for transactiva-
tion and DNA binding (10, 61). The results of the GST pulldown
assays demonstrated that WC5 does not affect the interaction of
IE2 with itself or with TBP in vitro (Fig. 1), suggesting that its
antiviral activity most likely does not stem from an interference
with these IE2 protein-protein interactions. This conclusion is
further sustained by the lack of any significant inhibitory activity
ofWC5 on the expression of a set of E2F-responsive cellular genes
which can be stimulated by either HCMV infection or IE2 expres-
sion (49) and which are thought to be indirectly regulated via
protein-protein interactions rather than direct binding of IE2 to
their promoters. In fact, the treatmentwithWC5of quiescent cells
either infected with HCMV or transduced with a recombinant
IE2-expressing AdV did not affect the stimulation of cellular
CDK2, RR1, and TSmRNAs (Fig. 2).
DNA-protein interactions are a traditional target of quinolone
antimicrobial agents (62); therefore, we next examined the effect
of WC5 on the most well-characterized interaction of IE2 with a
DNA element, namely, its binding to the crs of HCMVMIEP that
leads to the repression of IE gene expression (10). WC5 showed
the ability to abrogate the repression of MIEP exerted by the wt
IE2 protein, as well as by an IE2 mutant still able to repress the
MIEP but lacking transactivating activity (13). The results of the
EMSAs indicated that WC5 prevents the formation of an IE2-crs
FIG 7 WC5 inhibits the IE3-dependent transactivation of the early E1 gene
promoter of MCMV. NIH 3T3 cells were transfected with a plasmid contain-
ing luciferase reporter gene under the control of the E1 promoter (pE1-Luc) or
cotransfected with an IE3-expressing plasmid (pIE3) and then treated with
0.2%DMSO, 50MWC5,WC5E, or GCV. The reported values represent the
means 	 SD from three independent experiments in duplicate and are ex-
pressed as RLU. *, P 0.05 versus calibrator sample (pIE3 plus DMSO).
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complex (Fig. 4). Thus, it can be concluded that the abrogation of
the IE2-dependent repression of MIEP in transfected cells treated
withWC5 is due to interference with the binding of the protein to
the crs element. The 3-carboxylic acid moiety in the quinolone
scaffold of WC5 has been implicated in quinolone/nucleic acid
binding; thus, it might be involved in the interaction with the crs,
since the analog WC5E, which lacks this group due to esterifica-
tion, does not inhibit eitherHCMVreplication (30) or the binding
of IE2 to a crs-derived probe (Fig. 4).
AnotherHCMVpromoter regulated by IE2 is that of the essen-
tial gene UL54. We previously reported that WC5 interferes in
transfected cells with the IE2-dependent transactivation of a re-
porter construct bearing the entire promoter of UL54 (31). Here,
we have identified a minimal portion of the UL54 gene promoter
sufficient tomediate the sensitivity toWC5 in a segment of 150 bp
upstream from the transcription start site. In fact, according to
previous studies, this portion of the UL54 5=-flanking region me-
diates the IE2-dependent transactivation of the whole gene pro-
moter at a level comparable to that of the entire promoter (52).
Although the regulation of theUL54 promoter by IE2 has been the
subject of previous studies (52–54), the only cis-acting element in
the promoter with an established role in IE2-dependent transac-
tivation that has been characterized so far is the IR-1 sequence (54,
55). However, a direct binding of IE2 to the UL54 promoter has
not been detected, although IE2 and the cellular transcription fac-
tor Sp1 have been found as components of an IR-1 DNA-protein
complex that had been detected in extracts prepared from IE2-
overexpressingU373-MGcells (55). It was observed that the bind-
ing of Sp1 to the IR-1 element was strongly increased in the pres-
ence of IE2, thus suggesting that IE2 may induce a functional
modulation of Sp1 that enables it to bind IR-1, and that the asso-
ciation of IE2 with the IR-1 response element might occur
through this cellular factor (55). The inhibitory activity of WC5
on the transcriptional activity of pUL54-0.15 might thus stem
from interference with the formation of a transcriptional compe-
tent IR-1DNA-protein complex. In a previous study, we observed
thatWC5 did not exert any effect on two different viral promoters
that require Sp1 for their basal transcriptional activity, thus sug-
gesting that a direct interference of WC5 with the binding of Sp1
toDNA is unlikely (30). Sp1 is also involved in the activation of the
intercellular adhesion molecule-1 (ICAM-1) promoter by IE2,
and IE2 augments the transcriptional activity of the ICAM-1 pro-
moter in concert with pp71 (63). However, when the Sp1 site
within the ICAM-1 promoter was mutated, a residual (but lower)
promoter activity was still observed, thus suggesting that func-
tional Sp1 binding sites are not strictly essential for the IE2-medi-
ated transactivation of the ICAM-1 promoter. Here, a similar re-
sidual transactivation potential was observedwith the pUL54-0.15
IR-1mut construct, wherein the IR-1 elementwas inactivated (Fig.
5). The inhibitory effect ofWC5 on theminimal pUL54 construct
bearing a mutated IR-1 that was measured as well (Fig. 5) might
thus suggest that outside the IR-1 sequence, an additional IE2-
responsive DNA region(s) might be present. Further studies will
be required to identify possible additional IE2-responsive ele-
ments, if there are any.
Among those IE2 functions that require an interaction with
DNA regulatory elements, the inhibitory effect of WC5 seems to
be confined specifically to the regulation of viral elements, such as
MIEP and E gene promoters. In fact, we have observed that in cells
transfected with indicator constructs containing the promoter of
cellular cyclin E, WC5 does not significantly affect gene reporter
activity (Fig. 6A). The expression of the cyclin E gene is greatly
stimulated upon HCMV infection or IE2 expression (38, 49).
Moreover, it was observed that IE2 directly interacts with the cy-
clin E promoter, thus promoting its transactivation (38). In our
EMSAs, WC5 did not interfere with the binding of IE2 to a probe
derived from the cyclin E promoter (Fig. 6B), thus indicating that
not all IE2 functions that implicate direct or indirect binding to
DNA are targeted by WC5. Differences in the sequences of the
IE2-binding sites, their localizationwithin the promoters, the pos-
sible DNA secondary structures that might originate after IE2
binding, and IE2 interactions with specific cellular chromatin re-
modeling enzymes might account for the differential effects of
WC5 on IE2-responsive promoters. Once the crystallographic
structure of the IE2 bound to DNA is available, this and other
questions can be addressed.
The preference of WC5 for CMV promoters that emerged
from this study is in agreement with the specific antiviral activity
demonstrated by this compound against HCMV over other her-
pesviruses, such as herpes simplex virus 1 (HSV-1), and other
viruses, such as HIV-1, and also with the absence of any effect on
the transactivation of promoters of two constitutive cellular genes
and of HIV-1 long terminal repeat (LTR) (30, 34). Furthermore,
the inhibitory activity ofWC5 is specific for IE2 over IE1, the other
major protein product of the MIE gene locus that shares the first
85 amino acids with IE2. In fact, we observed that in transient
assays, WC5 did not interfere with the transactivation of the
thymidylate synthetase gene promoter, a specific IE1-responsive
promoter (50) (see Fig. S2 in the supplemental material available
at http://www.medicinamolecolare.unipd.it/sites/dipartimenti.it
/files/Supplemental%20Material.pdf).
In conclusion, we have identified a firstmechanismof action of
WC5 against HCMV in its ability to interfere with the interaction
of IE2 to crs within the MIEP, thus blocking its negative regula-
tion. The negative autoregulation of the MIEP by IE2 is essential
for efficient HCMV replication, since recombinant viruses that
fail to repress theMIEP have not been isolated (10, 21). A possible
indirect effect of WC5 on the IE2-dependent epigenetic mecha-
nisms that contribute to MIEP regulation cannot be excluded. In
fact, IE2-mediated negative regulation of the MIEP also depends
on its ability to recruit repressive chromatin remodeling enzymes
(23); thus, the interferencewith IE2 binding to crs exerted byWC5
might have an additional detrimental effect on the correct silenc-
ing of theMIEP and the progression of theHCMV cycle. A second
mechanismof action ofWC5 againstHCMVentails the inhibition
of IE2-dependent transactivation of viral E gene promoters that
are required for viral DNA replication and the progression of the
HCMV replication cycle, such as the UL54 and UL112-113 pro-
moters. Therefore, the inhibitory effect of WC5 on these two dif-
ferent IE2-dependent activities contributes to the overall anti-
HCMV activity.
WC5 may thus be an attractive candidate for a new class of
anti-HCMV drugs that exert their effects via novel pathways that
target IE functions. Our in vitro studies warrant further investiga-
tions to evaluate whether WC5 treatment may result in antiviral
activity in animal models of acute infection, as well as in reactiva-
tion from latency. Indeed, our experiments demonstrated that
WC5 is active against MCMV replication (30) and prevents the
transactivation of a prototypicMCMVE genemediated by the IE3
protein, the murine homolog of HCMV IE2. In fact, MCMV IE3
Mercorelli et al.
6624 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 O
ctober 23, 2014 by DIP DI SANITA PUBBLICA E M
ICRO
BIO
LO
G
IA
http://aac.asm
.org/
D
ow
nloaded from
 
shares a striking homology with IE2 not only at the amino acid
sequence level (the C-terminal 200 amino acids are identical, and
an additional 18 are conserved) but also in their regulatory func-
tions; indeed, IE3 is essential for virus growth, it exerts repressive
activity on its own ie1/ie3 promoter, and it is sufficient to activate
MCMV E gene expression (40, 60, 64). Given this high similarity
between HCMV IE2 and MCMV IE3, it is reasonable that the
inhibitory activity of WC5 is conserved, thus making possible the
investigation of the therapeutic potential of WC5 in the murine
model of cytomegalovirus infection.
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